Debora Stelitano, Simone La Frazia, Annalisa Ambrosino, Carla Zannella, Daniel Tay, Valentina Iovane, Serena Montagnaro, Anna De Filippis, Maria Gabriella Santoro, Matteo Porotto, Massimiliano Galdiero. Antiviral activity of nitazoxanide against infections.Journal of virus eradication. 2023, 9 (4): 100353
Caroline Schwarz, Raphael Schubert, Michael Schwarz, Angelika Schütz, Anika Jenke, David Bauer, Benjamin Steinwender, Enisa Gutic, Thomas Reiberger, Hans Haltmayer, Michael Gschwantler. CHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers.Journal of virus eradication. 2023, 9 (3): 100338
Hursch Patel, Karine Dubé. To prescreen or not to prescreen for broadly neutralizing antibody sensitivity in HIV cure-related trials.Journal of virus eradication. 2023, 9 (3): 100339
Eunice Akinyi Okumu, Gail E Henderson, Carol Golin, Kriste Kuczynski, Nuchanart Q Ormsby, Holly L Peay. Corrigendum to "HIV remission trial investigators' attitudes towards risk and risk mitigation in trials that include treatment interruption" [J Virus Erad 9 (2) (June 2023) 100331].Journal of virus eradication. 2023, 9 (3): 100340
Imran Jamal, Anisha Paudel, Landon Thompson, Michel Abdelmalek, Irfan A Khan, Vir B Singh. Sulforaphane prevents the reactivation of HIV-1 by suppressing NFκB signaling.Journal of virus eradication. 2023, 9 (3): 100341
Quinten Debrabander, Kathryn S Hensley, Christina K Psomas, Wichor Bramer, Tokameh Mahmoudi, Berend J van Welzen, Annelies Verbon, Casper Rokx. The efficacy and tolerability of latency-reversing agents in reactivating the HIV-1 reservoir in clinical studies: a systematic review.Journal of virus eradication. 2023, 9 (3): 100342
Anne Bruggemans, Gerlinde Vansant, Paulien Van de Velde, Zeger Debyser. The HIV-2 OGH double reporter virus shows that HIV-2 is less cytotoxic and less sensitive to reactivation from latency than HIV-1 in cell culture.Journal of virus eradication. 2023, 9 (3): 100343
Minhee Kang, Jennifer C Price, Marion G Peters, Sharon R Lewin, Mark Sulkowski. Design and analysis considerations for early phase clinical trials in hepatitis B (HBV) cure research: the ACTG A5394 study in persons with both HIV and HBV.Journal of virus eradication. 2023, 9 (3): 100344
Matthew C Pitman, Niamh Meagher, David J Price, Ajantha Rhodes, J Judy Chang, Barbara Scher, Brent Allan, Alan Street, James H McMahon, Thomas A Rasmussen, Paul U Cameron, Jennifer F Hoy, Stephen J Kent, Sharon R Lewin. Effect of high dose vitamin D on the HIV-1 reservoir: A pilot randomised controlled trial.Journal of virus eradication. 2023, 9 (3): 100345
Gilles Wandeler, Adria Ramirez Mena, Charles Kouanfack, Louise Fortes, Albert Gautier Ndione, Nabil Debzi, Karine Lacombe, Christine Katlama, Didier K Ekouevi, . Information and communication are key for hepatitis B elimination in Francophone Africa: Insights from a survey among healthcare providers.Journal of virus eradication. 2023, 9 (3): 100346
Jesper D Gunst, Nilu Goonetilleke, Thomas A Rasmussen, Ole S Søgaard. Immunomodulation with IL-7 and IL-15 in HIV-1 infection.Journal of virus eradication. 2023, 9 (3): 100347
Lijun Xu, Minghan Zhou, Xiuming Peng, Yufan Xu, Fan Huang, Linyun Wang, Xiaorong Peng, Zongxing Yang, Ran Tao, Guanjing Lang, Qing Cao, Minwei Li, Ying Huang, Biao Zhu, Yan Xu. The central nervous system is a potential reservoir and possible origin of drug resistance in hepatitis B infection.Journal of virus eradication. 2023, 9 (3): 100348